185 related articles for article (PubMed ID: 9148335)
1. [Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B].
Sampaio RN; Marsden PD
Rev Soc Bras Med Trop; 1997; 30(2):125-8. PubMed ID: 9148335
[TBL] [Abstract][Full Text] [Related]
2. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome.
Nonata R; Sampaio R; Marsden PD
Trans R Soc Trop Med Hyg; 1997; 91(1):77. PubMed ID: 9093636
[No Abstract] [Full Text] [Related]
3. Combined antimonial allopurinol therapy in mucosal leishmaniasis.
Sampaio RN; Marchán EM; Vexenat A; Tristão RJ; Marsden PD
Mem Inst Oswaldo Cruz; 1990; 85(3):373-4. PubMed ID: 2134714
[No Abstract] [Full Text] [Related]
4. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil.
Oliveira-Neto MP; Mattos M; Pirmez C; Fernandes O; Gonçalves-Costa SC; Souza CF; Grimaldi G
Rev Inst Med Trop Sao Paulo; 2000; 42(6):321-5. PubMed ID: 11136518
[TBL] [Abstract][Full Text] [Related]
5. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
[No Abstract] [Full Text] [Related]
6. High continuous antimony therapy in two patients with unresponsive mucosal leishmaniasis.
Marsden PD; Sampaio RN; Carvalho EM; Veiga JP; Costa JL; Llanos-Cuentas EA
Am J Trop Med Hyg; 1985 Jul; 34(4):710-3. PubMed ID: 2992304
[TBL] [Abstract][Full Text] [Related]
7. Mucosal leishmaniasis in Brazilian patients: two case reports with similar clinical presentation and different approaches.
Cruz AF; Resende RG; Albuquerque DR; de Lacerda JC; Leite CF; Ferreira Aguiar MC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Dec; 122(6):e199-e203. PubMed ID: 27234853
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
9. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol.
Antezana G; Zeballos R; Mendoza C; Lyevre P; Valda L; Cardenas F; Noriega I; Ugarte H; Dedet JP
Trans R Soc Trop Med Hyg; 1992; 86(1):31-3. PubMed ID: 1566297
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.
Goyonlo VM; Vahabi-Amlashi S; Taghavi F
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():177-179. PubMed ID: 31492621
[TBL] [Abstract][Full Text] [Related]
12. [Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis].
Romero GA; Lessa HA; Macêdo VO; Carvalho EM; Barral A; Magalhães AV; Orge MG; Abreu MV; Marsden PD
Rev Soc Bras Med Trop; 1996; 29(6):557-65. PubMed ID: 9011880
[TBL] [Abstract][Full Text] [Related]
13. [Visceral leishmaniasis: new drugs].
Minodier P; Robert S; Retornaz K; Garnier JM
Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
[TBL] [Abstract][Full Text] [Related]
14. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
15. [Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis].
Garcia Bustos MF; Barrio A; Parodi C; Beckar J; Moreno S; Basombrio MA
Medicina (B Aires); 2014; 74(5):371-7. PubMed ID: 25347898
[TBL] [Abstract][Full Text] [Related]
16. Treatment of imported New World cutaneous leishmaniasis in Germany.
Harms G; Scherbaum H; Reiter-Owona I; Stich A; Richter J
Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
[TBL] [Abstract][Full Text] [Related]
17. Retention of antimony in hair during leishmaniasis treatment.
Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
[No Abstract] [Full Text] [Related]
18. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
Yeşilova Y; Turan E; Sürücü HA; Aksoy M; Özbilgin A
Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of infantile visceral leishmaniasis].
Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
[TBL] [Abstract][Full Text] [Related]
20. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
